Hepatocellular carcinoma: Sorafenib - For once age is not an issue

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 5, 2014, Pages 273-274

  Dufour, Jean François ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADVANCED CANCER; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VULNERABLE POPULATION;

EID: 84900391783     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.48     Document Type: Article

References (7)

1. European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
2. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
3. Cheng, A. L. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
4. Jo, M. et al. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. Hepatol. Res. http://dx. doi. org/10. 1111/hepr. 12308.
5. Iavarone, M. et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54, 2055-2063 (2011).
6. Cho, J. Y. et al. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Liver Int. 33, 950-957 (2013).
7. Al Hasani, F. et al. Factors affecting screening for hepatocellular carcinoma. Ann. Hepatol. 13, 204-210 (2014).